Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,973
archived clinical trials in
High Cholesterol

Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  10/24/2013
Clinical Research Facility
1703
mi
from 98109
Kenosha, WI
Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 10/24/2013
Clinical Research Facility
1703
mi
from 98109
Kenosha, WI
Click here to add this to my saved trials
Effects of Niacin On Fatty Acid Trapping
Effect of Niacin On Fatty Acid Trapping
Status: Enrolling
Updated:  11/7/2013
Hospital of the University of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Effects of Niacin On Fatty Acid Trapping
Effect of Niacin On Fatty Acid Trapping
Status: Enrolling
Updated: 11/7/2013
Hospital of the University of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Effects of Niacin On Fatty Acid Trapping
Effect of Niacin On Fatty Acid Trapping
Status: Enrolling
Updated:  11/7/2013
Presbyterian Hospital
2371
mi
from 98109
Philadelphia, PA
Effects of Niacin On Fatty Acid Trapping
Effect of Niacin On Fatty Acid Trapping
Status: Enrolling
Updated: 11/7/2013
Presbyterian Hospital
2371
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Characterization of Dyslipidemia in Adolescent Obesity
Characterization of Dyslipidemia in Adolescent Obesity
Status: Enrolling
Updated:  11/13/2013
The Center For Nutrition and Preventive Medicine
2281
mi
from 98109
Charlotte, NC
Characterization of Dyslipidemia in Adolescent Obesity
Characterization of Dyslipidemia in Adolescent Obesity
Status: Enrolling
Updated: 11/13/2013
The Center For Nutrition and Preventive Medicine
2281
mi
from 98109
Charlotte, NC
Click here to add this to my saved trials
Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health
A Double-blinded, Placebo-controlled Randomized Trial Assessing the Extent to Which Consumption of Two Different Amounts of a Non-Pharmaceutical Food Supplement Can Improve Cardiovascular Health
Status: Enrolling
Updated:  11/21/2013
Integrative Health Technologies
1785
mi
from 98109
San Antonio, TX
Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health
A Double-blinded, Placebo-controlled Randomized Trial Assessing the Extent to Which Consumption of Two Different Amounts of a Non-Pharmaceutical Food Supplement Can Improve Cardiovascular Health
Status: Enrolling
Updated: 11/21/2013
Integrative Health Technologies
1785
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
952
mi
from 98109
Encino, CA
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
952
mi
from 98109
Encino, CA
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
919
mi
from 98109
Lancaster, CA
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
919
mi
from 98109
Lancaster, CA
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
1066
mi
from 98109
Spring Valley, CA
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
1066
mi
from 98109
Spring Valley, CA
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
1026
mi
from 98109
Aurora, CO
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
1026
mi
from 98109
Aurora, CO
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
2514
mi
from 98109
Safety Harbor, FL
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
2514
mi
from 98109
Safety Harbor, FL
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
2527
mi
from 98109
Tampa, FL
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
2527
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
1867
mi
from 98109
Indianapolis, IN
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
1867
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
1557
mi
from 98109
Iowa City, IA
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
1557
mi
from 98109
Iowa City, IA
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
1939
mi
from 98109
Louisville, KY
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
1939
mi
from 98109
Louisville, KY
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
1819
mi
from 98109
Bossier, LA
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
1819
mi
from 98109
Bossier, LA
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
2283
mi
from 98109
Charlotte, NC
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
2283
mi
from 98109
Charlotte, NC
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
2358
mi
from 98109
Raleigh, NC
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
2358
mi
from 98109
Raleigh, NC
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
1967
mi
from 98109
Cincinnati, OH
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
1967
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
1929
mi
from 98109
Toledo, OH
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
1929
mi
from 98109
Toledo, OH
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
2113
mi
from 98109
Knoxville, TN
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
2113
mi
from 98109
Knoxville, TN
Click here to add this to my saved trials
Cardiovascular Intervention Improvement Telemedicine Study
Cardiovascular Intervention Improvement Telemedicine Study
Status: Enrolling
Updated:  1/17/2014
Durham VA Medical Center
2338
mi
from 98109
Durham, NC
Cardiovascular Intervention Improvement Telemedicine Study
Cardiovascular Intervention Improvement Telemedicine Study
Status: Enrolling
Updated: 1/17/2014
Durham VA Medical Center
2338
mi
from 98109
Durham, NC
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
2124
mi
from 98109
Brimingham, AL
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
2124
mi
from 98109
Brimingham, AL
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
1106
mi
from 98109
Good Year, AZ
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
1106
mi
from 98109
Good Year, AZ
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
978
mi
from 98109
Lomita, CA
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
978
mi
from 98109
Lomita, CA
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
967
mi
from 98109
Rancho Cucamong, CA
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
967
mi
from 98109
Rancho Cucamong, CA
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
2714
mi
from 98109
Cooper City, FL
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
2714
mi
from 98109
Cooper City, FL
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
2724
mi
from 98109
Doral, FL
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
2724
mi
from 98109
Doral, FL
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
2717
mi
from 98109
Fort Lauderdale, FL
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
2717
mi
from 98109
Fort Lauderdale, FL
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
2715
mi
from 98109
Ft. Lauderdale, FL
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
2715
mi
from 98109
Ft. Lauderdale, FL
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
2730
mi
from 98109
Miami, FL
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
2730
mi
from 98109
Miami, FL
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
2730
mi
from 98109
Miami, FL
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
2730
mi
from 98109
Miami, FL
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
2722
mi
from 98109
Opa Locka, FL
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
2722
mi
from 98109
Opa Locka, FL
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
1733
mi
from 98109
Chicago, IL
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
1867
mi
from 98109
Indianapolis, IN
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
1867
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
2327
mi
from 98109
Oxon Hill, MD
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
2327
mi
from 98109
Oxon Hill, MD
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
1933
mi
from 98109
Detroit, MI
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
1933
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
2393
mi
from 98109
Linden, NJ
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
2393
mi
from 98109
Linden, NJ
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
2418
mi
from 98109
Wall, NJ
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
2418
mi
from 98109
Wall, NJ
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
2283
mi
from 98109
Charlotte, NC
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
2283
mi
from 98109
Charlotte, NC
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
2358
mi
from 98109
Raleigh, NC
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
2358
mi
from 98109
Raleigh, NC
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
2041
mi
from 98109
Akron, OH
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
2041
mi
from 98109
Akron, OH
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
1967
mi
from 98109
Cincinnati, OH
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
1967
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
2004
mi
from 98109
Columbus, OH
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
2004
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
1929
mi
from 98109
Toledo, OH
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
1929
mi
from 98109
Toledo, OH
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
2373
mi
from 98109
Philadelphia, PA
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
2132
mi
from 98109
Pittsburgh, PA
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
2132
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
2235
mi
from 98109
Simpsonville, SC
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
2235
mi
from 98109
Simpsonville, SC
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)
A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
2545
mi
from 98109
Winter Park, FL
Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)
A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
2545
mi
from 98109
Winter Park, FL
Click here to add this to my saved trials
Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)
A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
1681
mi
from 98109
Milkwaukee, WI
Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)
A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
1681
mi
from 98109
Milkwaukee, WI
Click here to add this to my saved trials